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BACKGROUND: Squamous cell carcinoma of the conjunctiva (SCCC) is associated with HIV-related immunosuppression, but human
papillomavirus virus (HPV) is also suspected to have a role. We carried out a case–control study to assess the role of cutaneous and
mucosal HPV types in SCCC, conjunctival dysplasia, and their combination (SCCC/dysplasia) in Uganda.
METHODS: We compared HPV prevalence in frozen biopsies from 94 SCCC cases (79 of whom were found to be HIV-positive), 39
dysplasia cases (34 HIV-positive), and 285 hospital controls (128 HIV-positive) having other eye conditions that required surgery.
Highly sensitive PCR assays that detect 75 HPV types were used. Odds ratios (ORs) and 95% confidence intervals (CIs) were
computed, adjusting for, or stratifying by age, sex, and HIV status.
RESULTS: Cutaneous HPV types were detected in 45% of SCCC cases, 41% of dysplasia cases and 11% of controls. Human
papillomavirus virus 5 and 8 were the most common types in SCCC, and most often occurred in combination with other types.
Associations were observed between SCCC/dysplasia and detection of both single (OR¼2.3; 1.2–4.4) and multiple (OR¼18.3;
6.2–54.4) cutaneous HPV types, and were chiefly based on findings in HIV-positive patients. Cutaneous HPV infections were rarely
observed among HIV-negative patients and the association with SCCC/dysplasia was not significant (OR¼2.4; 0.6–9.6) among them.
Squamous cell carcinoma of the conjunctiva/dysplasia risk and mucosal HPV types were not associated in either HIV-positive or
HIV-negative patients.
CONCLUSIONS: We detected cutaneous HPV types in nearly half of SCCC/dysplasia cases and often multiple types (HPV5 and 8 being
most common). The role of HIV (confounder or strong enhancer of cutaneous HPV carcinogenicity) is still uncertain.
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Since 1980s there has been a substantial increase in the number of
reported cases of squamous cell carcinoma of the conjunctiva
(SCCC), mainly in sub-Saharan Africa (Poole, 1999; Wabinga et al,
2000). The spread of human immunodeficiency virus (HIV)
infection has been implicated in the rise of SCCC incidence both
in Africa (Ateenyi-Agaba, 1995; Newton et al, 2001; Waddell et al,
2006) and the United States (Guech-Ongey et al, 2008), with
an approximately 10-fold increased risk in individuals with
HIV/AIDS. Mucosal human papillomavirus (HPV) types were
initially suspected to have a role in SCCC onset because of their
importance in the aetiology of carcinomas of the anogenital tract
and oropharynx (IARC, 2007). However, three small case–control
studies from Uganda (Ateenyi-Agaba et al, 2004; Tornesello et al,
2006; de Koning et al, 2008) have suggested that cutaneous HPV
types (i.e., types belonging to the genus beta and formerly referred
to as Epidermodysplasia Verruciformis HPV types; IARC, 2007) are
more likely candidates for the causation of SCCC than mucosal
HPV types.
This case–control study of SCCC and conjunctival dysplasia was
carried out in Uganda to further explore the role of HPV and HIV
infection in SCCC risk.
MATERIALS AND METHODS
Study participants
From January 2004 to June 2007, 125 and 17 patients admitted to
the Departments of Ophthalmology of Mulago Hospital, Kampala,
and Jinja Hospitals, Jinja, Uganda, respectively, for eye lesions
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ssuspected to be SCCC were invited to participate in this study as
cases. None had ever been included in previous scientific studies.
Conjunctival biopsies from these patients were divided: one part
was frozen and one part was fixed in 10% formalin and embedded
in paraffin. Three histological slides were stained with haematox-
ylin/eosin and initially read by a pathologist (EO) at the
Department of Pathology, Makerere University, Kampala, Uganda,
and then by two independent pathologists from DDL Diagnostic
Laboratory, Voorburg, the Netherlands. In case of disagreement on
the presence of SCCC or dysplasia, a fourth expert pathologist in
Kampala reviewed the slides. A consensus was achieved on the
presence of SCCC in 100 patients. A diagnosis of conjunctival
dysplasia was made in the remaining 42 patients.
Eligible controls were patients who had been admitted to the
same hospitals as cases for eye conditions other than SCCC or
dysplasia, and required surgical intervention. This allowed for the
collection of conjunctival biopsies that were subsequently frozen.
Controls were frequency-matched by hospital and sex, and had to
fall into the same expected age range as cases (i.e., 15–80 years).
The most frequent diagnoses were cataract (37%), chalazia (12%),
corneal tears (10%), and eye trauma (9%). Patients presenting with
pterygium or pingueculum were not included because it was
previously suspected that these diseases were associated with HPV
infection (Gallagher et al, 2001). A total of 309 controls were
included. A 10-ml blood sample was collected from cases and
controls in a tube containing EDTA. They were also asked to
answer a questionnaire providing information on selected socio-
demographic and lifestyle characteristics. All participants or their
guardians (in the case of minors) signed an informed consent form
and the study was approved by the ethics committees of Makerere
University and Uganda National Council for Science and
Technology.
HPV testing
Conjunctival biopsy samples from cases and controls were frozen
at  801C and shipped to DDL Diagnostic Laboratory, a certified
and dedicated PCR laboratory, which conducted strict separation
of clean reagents, DNA isolation, PCR, and post-PCR activities.
Five SCCC cases, two dysplasia cases, and 19 controls had no
biopsies because of losses, or empty or mislabelled tubes, and were
excluded from this study. The DNA was extracted by proteinase K
treatment. Each step of the described procedures comprised HPV-
negative and -positive controls. For every 10 tissue samples, one
DNA isolation-negative control was included. For each run a
positive control was included.
Isolated DNA was tested using three different PCR-based assays,
one targeting b-globin (for DNA quality control), one targeting
mucosal HPV types, and one targeting cutaneous HPV types.
b-globin-negative biopsy samples (one SCCC case, one dysplasia
case, and five controls) were also excluded.
Testing for mucosal HPV types was carried out using the short
PCR fragment (SPF)10-line probe assay (LiPA)25-DNA enzyme
immunoassay (DEIA) system, (version 1, Labo Bio-Medical
Products, Rijswijk, the Netherlands) as described previously
(Kleter et al, 1998, 1999). Briefly, the broad spectrum SPF10 PCR
amplifies a 65-bp fragment from the L1 region of the HPV genome.
Amplimers were captured onto streptavidin-coated microtitre
plates using biotinylated reverse primers. After denaturation of
the PCR products by alkaline treatment, a DEIA was used to
detect HPV-positive samples. This method is able to detect more
than 50 HPV types (van Doorn et al, 2006). Amplimers from SPF10
PCR DEIA-positive samples were used for subsequent genotyping
of 25 mucosal HPV types (high-risk: HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, 68, and 70; low-risk: HPV6, 11, 34, 40,
42–44, 53, 54, and 74). The LiPA25 SPF10 DEIA-positive samples,
which were negative on the LiPA25 strip, were tested on an
additional strip containing probes for 17 additional mucosal HPV
types (HPV26, 30, 55, 61, 62, 64, 67, 69, 71, 82, 83, 84, 85, 87, 89, 90,
and 91).
Testing for cutaneous HPV types was performed using a PCR
reverse hybridisation assay method (The skin [beta] HPV
Prototype Research Assay; Diassay BV, Rijswijk, the Netherlands;
de Koning et al, 2006). It consists of a broad spectrum PCR
specifically designed for the amplification of the b-HPV genus and
targets a fragment of 117bp from the E1 region of the HPV
genome. Combined with the reverse hybridisation assay, the
method allows the detection of 25 cutaneous HPV types (i.e.,
HPV5, 8, 9, 12, 14, 15, 17, 19–25, 36–38, 47, 49, 75, 76, 80, 92, 93,
and 96). As no DEIA had been developed for this assay, all
amplimers were directly analysed by reverse hybridisation assay.
The sensitivity of PCR assays used in this study for the detection
of mucosal HPV types (o100 copies; Kleter et al, 1999) was
slightly higher than the sensitivity of the PCR assays used to detect
cutaneous HPV types (100–1000 copies; de Koning et al, 2006).
HIV testing and AIDS diagnosis
The HIV testing was done at the Nakasero Blood Bank in Kampala,
Uganda using an enzyme-linked immunosorbent assay (Murex
HIV-1.2.0, Murex Biotech, Dartford, United Kingdom) that is
reported to have 99.9% specificity and 100% sensitivity. The HIV-
positive findings were confirmed using western blot analysis and
all HIV-positive patients received post-test counselling. The
diagnosis of AIDS was based on the presence of cytomegalovirus
retinitis, cryptococcal meningitis, or skin rash with weight loss.
Statistical analysis
The association of SCCC, dysplasia or (when findings were similar)
their combination (SCCC/dysplasia) with various characteristics,
and the positivity for mucosal and cutaneous HPV types was
evaluated using unconditional multiple logistic regression equa-
tions. Odds ratios (ORs) and corresponding 95% confidence
intervals (CIs) were calculated after adjustment for age (as a
continuous variable) and sex. All analyses were also adjusted for,
or stratified by, HIV status.
RESULTS
A total of 94 SCCC cases (mean age: 36.7; range: 15–80 years), 39
dysplasia cases (mean age: 32.8; range: 11–50 years), and 285
controls (mean age: 34.0; range: 15–80 years) with HPV results
were included in this study. Education, occupation, and cigarette
smoking were not related to the risk of SCCC/dysplasia (Table 1).
An association (OR¼7.3; 95% CI: 4.2–12.4) was seen with
HIV infection, which was detected in 85% of cases and 45% of
controls. The diagnosis of AIDS was associated with increased risk
of SCCC/dysplasia among HIV-positive patients (OR¼5.6; 95%
CI: 1.5–20.3).
Mucosal HPV types were detected in 6.4, 7.7, and 3.5% of SCCC
cases, dysplasia cases, and controls, respectively, and the majority
were uncharacterised types (Table 2). Cutaneous HPV types were
observed in 44.7, 41.0, and 10.5% of SCCC cases, dysplasia cases,
and controls, respectively, and there were few uncharacterised
types. Multiple-type infections were detected in 57.1% of SCCC
cases, 75.0% of dysplasia cases and 13.3% of controls. The most
common types among SCCC cases were HPV5 (n¼15), 8 (n¼16),
and 24 (n¼9). Human papillomavirus 5, 14, and 17 were each
observed in at least five dysplasia cases. Human papillomavirus 5,
15, and 24 were each observed in at least five controls and only
four controls had multiple infections. The few mucosal or
cutaneous HPV types detected among HIV-negative cases and
controls are shown in parentheses (Table 2).
Table 3 shows the OR values of SCCC, dysplasia, and their
combination by positivity for different HPV type(s) after adjust-
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sment for age, sex, and HIV status. No association emerged between
infection with mucosal HPV types and either SCCC or dysplasia
(OR for SCCC/dysplasia¼1.0; 95% CI: 0.4–2.7). Among
HIV-positive patients the corresponding OR was 1.4 (95% CI:
0.5–3.8 (data not shown)). In contrast, positivity for cutaneous
HPV types was associated with significantly increased risks for
SCCC/dysplasia (OR ¼2.3; 95% CI: 1.2–4.4 for single infection
and OR ¼18.3; 95% CI: 6.2–54.4 for multiple infections).
Significantly elevated OR values for SCCC/dysplasia were observed
for five of the six most common types (i.e., HPV5, 8, 14, 17, and
23), whereas the OR value was also of borderline statistical
significance for HPV24. In general, OR values for individual
cutaneous types were similar for SCCC and dysplasia except for
HPV8 that showed a stronger association with SCCC (OR¼39.0;
95% CI: 4.9–310) than with dysplasia (OR¼11.3; 95% CI:
1.0–134). The difference between the two OR values was not,
however, statistically significant. When cases with well-differen-
tiated and poorly differentiated SCCC were evaluated separately,
no differences in the positivity for cutaneous HPV types emerged
(data not shown).
The associations of SCCC/dysplasia with cutaneous HPV are
shown separately based on the HIV status in Table 4. The OR
values very similar to those shown in Table 3 for all study subjects
were observed among HIV-positive patients (OR for single and
multiple cutaneous HPV infections¼2.7; 95% CI: 1.3–5.6 and
15.4; 95% CI: 5.2–45.5, respectively; Table 4). The OR values for
individual HPV types in HIV-positive patients (data not shown)
were also similar to those in all study subjects. The OR for
cutaneous HPV positivity among HIV-negative patients (2.4) had
extremely broad CI values (0.6–9.6).
DISCUSSION
Our study, to the best of our knowledge, is the largest so far on
HPV infection and risk of SCCC and conjunctival dysplasia and
lends further support to the hypothesis (Ateenyi-Agaba et al, 2004;
de Koning et al, 2008) that cutaneous, but not mucosal, HPV types
may be involved in the aetiology of this rare malignancy and its
precursor lesion, dysplasia. Our study also showed, however, that
cutaneous HPV infection and SCCC/dysplasia were seldom
observed in the absence of HIV infection. It remains, therefore,
difficult to establish whether the association between SCCC/
dysplasia and cutaneous HPV is entirely attributable to the
confounding effect of HIV infection, or whether HIV acts as a
strong enhancer of the ability of cutaneous HPV types to induce
cancer in the conjunctiva. However, we observed a strong
difference in the OR values for SCCC/dysplasia between patients
who were positive for both HIV and cutaneous HPV (OR¼26.0;
95% CI: 12.5–54.1) and those infected with HIV only (OR¼4.8;
95% CI: 2.6–8.8) compared with double-negative patients (data
not shown). A hint of an association with cutaneous HPV was also
observed among HIV-negative individuals, but it was far from
being statistically significant. The lack of cutaneous HPV infection
in half of SCCC/dysplasia cases detracts from the possibility of the
infection to be the necessary cause of SCCC (as mucosal HPVs are
for cervical cancer, IARC, 2007), but must be interpreted
cautiously because at present even the best tests for cutaneous
HPV may have less than perfect sensitivity.
This study does not allow us to draw conclusions on the cancer-
causing potential of individual cutaneous HPV types, as a majority
of the cases harboured multiple types. In fact, the risk of SCCC/
dysplasia seemed to be substantially higher in the presence of
multiple than single infections, even after allowance for HIV status.
Individually, HPV5 and 8 were the most frequently detected types
in SCCC/dysplasia cases, followed by HPV14, 17, 23, and 24.
Human papillomavirus 5, 8, 14, and 24 belong to the b-1 species
and are commonly associated with skin lesions in Epidermodys-
plasia verruciformis and in immunosupressed individuals (IARC,
2007). They are mainly associated with benign lesions, but have
also been detected in malignant lesions in both immunosuppressed
and immunocompetent individuals. Previous case–control studies
on SCCC also identified HPV5 (Ateenyi-Agaba et al, 2004; de
Koning et al, 2008), HPV8 (Ateenyi-Agaba et al, 2004; de Koning
et al, 2008) HPV14 (Ateenyi-Agaba et al, 2004; Tornesello et al,
2006; de Koning et al, 2008), and HPV24 (Ateenyi-Agaba et al,
2004) in SCCC biopsies.
Interestingly, we observed a tendency of infection with HPV8 to
increase as lesions worsened (from 0.4% among controls to 5.1 and
17.0% among dysplasia and SCCC cases, respectively). This
tendency derived entirely from findings among HIV-positive
patients. Among HIV-nagative patients HPV8 was dectected in
only one SCCC case and no controls, which raises, for the first
time, the possibility that a cutaneous type, HPV8, might be a ‘high-
risk’ cutaneous type. The classification of HPV types into
high- and low-risk types, based on the change in their prevalence
from less to more severe neoplastic lesions, has been essential in
understanding the role of mucosal HPV infection in cervical cancer
(IARC, 2007). A similar classification would greatly help elucidate
the role of cutaneous HPV types in SCCC and skin carcinoma. The
early genes of HPV8 have been shown to be expressed in the
epidermis and to induce spontaneous benign and malignant skin
lesions in transgenic mouse models (Schaper et al, 2005).
Lack of association of SCCC risk with mucosal HPV types either
in HIV-positive or HIV-negative patients in our study is in
agreement with most recent studies (for review, see de Koning et al
Table 1 Distribution of 133 cases of SCCC/dysplasia and 285 controls
a
by selected characteristics and corresponding ORs and 95% CIs
SCCC/dysplasia Controls
N (%) N (%) OR (95% CI)
b
Age (years)
o35 63 (47.4) 160 (56.1)
35–44 47 (35.3) 67 (23.5)
X45 23 (17.3) 58 (20.4)
Sex
Male 57 (42.9) 134 (47.0)
Female 76 (57.1) 151 (53.0)
Education
Illiterate or primary 78 (58.7) 156 (54.7) 1
c
Secondary or higher 55 (41.4) 129 (45.3) 1.0 (0.6–1.7)
Occupation
Indoor 35 (26.3) 66 (23.2) 1
c
Outdoor 98 (73.7) 218 (76.8) 0.8 (0.5–1.4)
Cigarette smoking
No 118 (88.7) 249 (87.7) 1
c
Yes 15 (11.3) 35 (12.3) 0.9 (0.4–1.9)
HIV status
Negative 20 (15.0) 157 (55.1) 1
c
Positive 113 (85.0) 128 (44.9) 7.3 (4.2–12.4)
AIDS
d
No 100 (88.5) 125 (97.7) 1
c
Yes 13 (11.5) 3 (2.3) 5.6 (1.5–20.3)
Abbreviations: CI¼confidence interval; OR¼odds ratio; SCCC¼squamous cell
carcinoma of the conjunctiva.
aSome figures do not add up due to missing values.
bAdjusted for age, sex and HIV status, as appropriate.
cReference category.
dAmong
HIV-positive only.
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s(2008)). Notably, of the few infections with mucosal HPV types in
our study, most could not be assigned to any of the 42 most
common mucosal HPV types for which we performed genotyping.
The SPF10 PCR we used for mucosal HPV types includes broad-
spectrum primers that preferentially amplify mucosal types, but
also allows for the amplification of some cutaneous HPV types. It
is, therefore, possible that the uncharacterised HPV types detected
by assays targeting mucosal types were actually low-viral-copy
cutaneous HPV infections (de Koning et al, 2008). In fact, all SCCC
and dysplasia cases, as well as three out of seven controls with
uncharacterised mucosal HPV types also harboured cutaneous
HPV types.
The conjunctiva is the only site in equatorial Africans that is not
protected from ultraviolet light by heavy pigmentation (Waddell
et al, 2006). A causal role of heavy ultraviolet light exposure in
SCCC onset is strongly supported by the geographical distribution
of the disease (IARC, 2007; Guech-Ongey et al, 2008), and by the
preferential onset of the malignancy in the intra-palpebral zone
that is the part of the conjunctiva most heavily exposed to
ultraviolet light (Waddell et al, 2006). It can probably be assumed
that all Ugandans are heavily exposed to ultraviolet light and it is
therefore not surprising that no clear association was observed
between outdoor occupation and SCCC risk in our study.
Education level and cigarette smoking were also unrelated to
SCCC risk.
The important strengths of our study include the larger number
of cases and controls compared with previous studies (de Koning
et al, 2008); the exclusion from the control group of any condition
suspected to be associated with HPV infection; the availability of
frozen biopsy samples for both cases and controls (shown to be
better for detection of cutaneous HPV types than paraffin biopsies)
(Pfister et al, 2003); and the use of highly sensitive and specific PCR
assays able to recognise a wide range of mucosal and cutaneous
HPV types. In fact, compared with previous studies (Ateenyi-Agaba
et al, 2004; Tornesello et al, 2006; de Koning et al, 2008), we
observed a higher proportion of SCCC positive for cutaneous HPV
types (45%) and fewer uncharacterised cutaneous HPV types.
Nevertheless, the family of cutaneous HPV types is broad and
heterogeneous (IARC, 2007), so false-negative results cannot be
excluded. As expected from what is known about HPV-associated
anogenital carcinogenesis (IARC, 2007), dysplasias harboured
cutaneous HPV types approximately as often as SCCC.
The weaknesses of this study include lack of information on
HPV viral load and HPV subtypes and variants. However, there is
at present no evidence that cutaneous HPV subtypes and variants
have any clinical relevance. Information on CD4þ count was not
Table 2 Prevalence of HPV types among cases of SCCC and dysplasia and among controls
SCCC (n¼94) Dysplasia (n¼39) Controls (n¼285)
HPV type Single
a Multiple
a Total (%) Single
a Multiple
a Total (%) Single
a Multiple
a Total (%)
Mucosal
None 88 (93.6) 36 (92.3) 275 (96.5)
Any 6 6 (6.4) 3 3 (7.7) 8 (1) 2 10 (3.5)
16 1 1 2 (0.7)
45 1 1 (1.1)
52 2 2 (0.7)
53 2 2 (0.7)
83 1 1 (2.5)
Uncharacterised 5 5 (5.3) 2 2 (5.1) 7 (1) 7 (2.5)
Cutaneous
None 52 (55.3) 23 (59.0) 255 (89.5)
Any 18 (1) 24 (1) 42 (44.7) 4 12 (1) 16 (41.0) 26 (11) 4 30 (10.5)
5 2 13 15 (16.0) 8 8 (20.5) 5 (2) 2 7 (2.5)
8 5 11 (1) 16 (17.0) 2 2 (5.1) 1 1 (0.4)
9 1 1 (1.1) 1 (1) 1 (2.6) 1 (1) 1 (0.4)
12 4 4 (4.3) 1 1 (0.4)
14 1 7 8 (8.5) 6 6 (15.4) 3 3 (1.1)
15 1 1 (2.6) 6 (3) 1 7 (2.5)
17 1 3 4 (4.3) 1 4 5 (12.8)
19 1 1 (1.1) 2 2 (5.1)
20 4 4 (4.3) 1 1 (2.6) 1 1 (0.4)
21 1 (1) 3 4 (4.3) 1 1 (0.4)
22 1 1 2 (2.1) 2 (1) 2 (5.1) 2 (1) 2 4 (1.4)
23 6 6 (6.4) 2 2 (5.1) 1 1 (0.4)
24 3 6 9 (9.6) 1 1 2 (5.1) 4 (1) 2 6 (2.1)
25 1 1 (1.1) 1 1 (2.6)
36 1 1 (1.1)
37 2 2 (2.1) 1 1 (2.6)
38 1 3 4 (4.3)
49 2 2 (2.1)
75 2 (1) 2 (2.1)
76 1 1 (1.1) 1 1 (2.6) 2 (2) 2 (0.7)
80 1 1 (1.1) 1 1 (2.6)
92 1 1 (1.1)
93 1 1 (1.1)
96 1 1 (1.1) 1 (1) 1 (2.6)
Uncharacterised 1 1 (1.1) 4 (1) 4 (1.4)
Abbreviations: HPV¼human papillomavirus; SCCC¼squamous cell carcinoma of the conjunctiva.
aNumber of HIV-negative subjects, if any, are shown in parentheses.
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and presence of AIDS was observed.
Finally, many more studies exist on cutaneous HPV types and
non-melanomatous skin cancer than on SCCC (IARC, 2007).
Notwithstanding, the evidence for an association with cutaneous
HPV types is stronger and more consistent for SCCC than for
non-melanomatous skin cancer (Bouvard et al, 2009). Differences
in the importance or detectability of cutaneous HPV types between
SCCC and non-melanomatous skin cancer may derive from
differences in the epithelia of origin (i.e., conjunctiva, the thinnest
mucosal membrane in the body, and skin, a stratified squamous
epithelium). It is also noteworthy, however, that the control
samples used in studies on SCCC (i.e., biopsies from exactly the
same location as SCCC) were probably more appropriate than
Table 4 ORs for SCCC/dysplasia and corresponding 95% CIs based on the presence of cutaneous HPV infection and HIV status
HIV
Negative Positive
Cutaneous HPV Cases:controls OR (95% CI)
a Cases:controls OR (95% CI)
a
Negative
b 17:146 1 58:109 1
Single infection 1:11
2.4 (0.6–9.6)
21:15 2.7 (1.3–5.6)
Multiple infection 2:0 34:4 15.4 (5.2–45.5)
Abbreviations: CI¼confidence intervals; HPV¼human papillomavirus; OR¼odds ratio; SCCC¼squamous cell carcinoma of the conjunctiva.
aAdjusted by age and sex.
bReference category.
3
5
Table 3 ORs for SCCC and dysplasia and corresponding 95% CIs based on the presence of HPV infection
Controls (n¼285) SCCC (n¼94) Dysplasia (n¼39) SCCC/dysplasia
HPV type N (%) N (%) OR (95% CI)
a N (%) OR (95% CI)
a N (%) OR (95% CI)
a
Mucosal
Negative
b 275 (96.5) 88 (93.6) 1 36 (92.3) 1 124 (93.2) 1
Single 8 (2.8) 6 (6.4)
 
1.0 (0.3–2.9) 3 (7.7)
 
1.2 (0.3–4.7) 9 (6.8)
 
1.0 (0.4–2.7)
Multiple 2 (0.7) 0 0 0
Cutaneous
Negative
b 255 (89.5) 52 (55.3) 1 23 (59.0) 1 75 (56.4) 1
Single 26 (9.1) 18 (19.2) 2.7 (1.3–5.6) 4 (10.3) 1.3 (0.4–4.2) 22 (16.5) 2.3 (1.2–4.4)
Multiple 4 (1.4) 24 (25.5) 17.0 (5.5–52.5) 12 (30.8) 18.9 (5.4–66.4) 36 (27.1) 18.3 (6.2–54.4)
HPV5
Negative
b 278 (97.5) 79 (84.0) 1 31 (79.5) 1 110 (82.7) 1
Single 5 (1.8) 2 (2.1)
 
4.8 (1.8–12.8) 0
 
6.1 (1.9–19.3) 2 (1.5)
 
5.1 (2.0–12.7)
Multiple 2 (0.7) 13 (13.8) 8 (20.5) 21 (15.8)
HPV8
Negative
b 284 (99.7) 78 (83.0) 1 37 (94.9) 1 115 (86.5) 1
Single 1 (0.4) 5 (5.3)
 
39.0 (4.9–309.6) 0
 
11.3 (1.0–134.0) 5 (3.8)
 
30.3 (3.8–239.9)
Multiple 0 11 (11.7) 2 (5.1) 13 (9.8)
HPV14
Negative
b 282 (99.0) 86 (91.5) 1 33 (84.6) 1 119 (89.5) 1
Single 0 1 (1.1)
 
4.7 (1.2–18.3) 0
 
8.0 (1.9–34.3) 1 (0.8)
 
5.8 (1.6–20.8)
Multiple 3 (1.1) 7 (7.5) 6 (15.4) 13 (9.8)
HPV17
Negative
b 285 (100.0) 90 (95.7) 1 34 (87.2) 1 124 (93.2) 1
Single 0 1 (1.1)
 
N (3.0–N) 1 (2.6)
 
N (9.1–N) 2 (1.5)
 
N (5.4–N)
Multiple 0 3 (3.2) 4 (10.3) 7 (5.3)
HPV23
Negative
b 284 (99.7) 88 (93.6) 1 37 (94.9) 1 125 (94.0) 1
Single 0 0
 
8.6 (1.0–74.0) 0
 
9.0 (0.8–105.7) 0
 
9.2 (1.1–75.3)
Multiple 1 (0.4) 6 (6.4) 2 (5.1) 8 (6.0)
HPV24
Negative
b 279 (97.9) 85 (90.4) 1 37 (94.9) 1 122 (91.7) 1
Single 4 (1.4) 3 (3.2)
 
2.6 (0.9–8.0) 1 (2.6)
 
1.5 (0.3–8.3) 4 (3.0)
 
2.3 (0.8–6.8)
Multiple 2 (0.7) 6 (6.4) 1 (2.6) 7 (5.3)
Abbreviations: CI¼confidence intervals; HPV¼human papillomavirus; OR¼odds ratio; SCCC¼squamous cell carcinoma of the conjunctiva.
aAdjusted by age, sex and HIV
status.
bReference category.
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sthose included in cases–control studies of skin cancer (i.e., a
variety of healthy skin samples but mainly plucked eyebrow hairs)
(IARC, 2007).
In conclusion, to determine whether any individual cutaneous
HPV type is aetiologically important, or simply a correlate of
immunosuppression, will require molecular studies of their
presence in tumour cells (Quint et al, 2009).
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